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Abstract
Introduction Providing health care to patients at home could be causing the mortality and readmission rates reduction in addition
to satisfaction of both patients and health care providers increase. The aim of this study was to assess the cost-effectiveness of
home care service compared to hospital based care in patients with diabetic foot ulcer.
Methods An economic evaluation study and a trial study were simultaneously conducted in Iran. In trial phase, patients with
diabetic foot ulcer were randomly assigned to the home care or hospital care. The Cost and Quality of life data were determined as
measures of the study. Incremental cost-effectiveness ratio was calculated for comparative purposes. The model consisted of five
stages of the disease. The Tree Age Pro 2009 and R software’s were used for data analysis.
Results 120 patients were enrolled in our trial; among which 30 patients were in home care service group and 90 patients in
hospital based care group. The rate of ulcer size reduction in hospital based care was significant (P value = 0.003) in comparison
with home care service. The total cost of the home care and hospital strategies were 1720.4 US$, 3940.3 US$ and the total
effectiveness were 0.31 and 0.29, respectively. The incremental cost-effectiveness ratio (ICER) was 117,300 US$ per quality-
adjusted life year for home care intervention compared to hospital based care. Based on ICER plane home care treatment will be
placed on the southeastern quadrant of the Cost-Effectiveness Plane, and is suggested as a more dominant treatment alternative.
Conclusions Regarding current evidence, home care strategy for patients suffering diabetic foot ulcer enjoys more cost effec-
tiveness compared to hospital care. It is suggested that healthcare policy makers determine the tariff for health care services for
disease groups according to the activity based costing approach.
Keywords Economic evaluation . Diabetes . Diabetic foot . Cost effective . Randomized trial
* Zh Najafpour
najafpour-zh@ajums.ac.ir












1 Shariati Hospital, Tehran University of Medical Sciences,
Tehran, Iran
2 Diabetes Research Center, Endocrinology and Metabolism Clinical
Sciences Institute, Tehran University of Medical Sciences,
Tehran, Iran
3 Department of Medical Education, Center for Educational Research
in Medical Sciences (CERMS), School of Medicine, Iran University
of Medical Sciences, Tehran, Iran
4 Department of Pharmacoeconomics and pharmaceutical
administration, Faculty of Pharmacy, Tehran University of Medical
Sciences, Tehran, Iran
5 Department of Health care Management, School of Public Health,
Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
6 Endocrinology andMetabolism Research Center, Endocrinology and
MetabolismClinical Sciences Institute, TehranUniversity ofMedical
Sciences, Tehran, Iran
Journal of Diabetes & Metabolic Disorders
https://doi.org/10.1007/s40200-020-00527-y
Introduction
The rapid rise in the incidence of diabetes, a serious lifelong
condition, is of alarming concern to health care system.
Recent data from the World Health Organization (WHO) es-
timate that by the year 2025, more than 325 million people
worldwide will be diagnosed with diabetes [1].
Diabetic foot ulceration is one of the most common com-
plications of diabetes disease and is notorious for its complex-
ity and healing difficulties [2]. The prevalence of foot ulcers
ranges from 4% to 10% among individuals with diabetes
mellitus [3]. Diabetic foot ulcers (DFU) frequently become
infected and are a major.
limb amputations in. Approximately 56% of DFUs become
infected during their life cycle [4], and 20% of these patients
with infected foot wounds require radical debridement of soft
tissue and bone, resulting in some form of lower extremity
amputation. The ensuing large wound deficit often requires
prolonged healing time and extended hospital stays with a
further risk for reinfection. Furthermore, this lengthened and
sometimes interrupted healing process impairs patient mobil-
ity; causes substantial lost productivity; diminishes quality of
life; imposes tremendous medical, psychosocial and financial
impacts and presents a significant management challenge to
health care professionals [5]. Then diabetic foot ulcers impose
tremendous medical and financial burden on our health care
system with conservative cost estimates as high as US$
45,000 per patient [6]. These estimations, however, do not
include the deleterious psychosocial effects on the patient’s
quality of life because of impaired mobility and substantial
loss of productivity [7].
Hospital in the home (HiTH) services may offer one
means of reducing admission in the hospital demand that
result in facilitating the more efficient use of inpatient beds,
providing an alternative to in-hospital admission and en-
abling patients to be transferred home earlier, thereby in-
creasing inpatient bed availability. In other words, a poten-
tial to avoid the significant capital costs associated with
building and running large hospitals is possible through
the utilization of Hospital in the home services [8].
Ambulatory setting would be a representative for the mini-
mum total cost which invest in a tertiary centres [9]. There is
different estimation for economic cost of DFU management
in different countries. The result of a comparison between
five different countries showed that DFU treatment varied
from Int$102 in Tanzania (as the lowest cost) to Int$188,645
in the USA (the highest cost). The prolonged and infected
wounds in complicated patients with a number of comor-
bidities is associated with increasing costs [10].In this re-
gard a systematic review suggested that homecare for dia-
betic patients suffering DFU not only reduces the cost of
hospitalization and re-hospitalization because of DFU, but
also increases the patient health outcomes [11].
As an advantage of home care for DFU management, one
study indicated that the storage of open-but-unused wound
dressings (which inevitably saved at home) compared to new-
ly opened ones did not increase the rate of microbial contam-
ination [12]. However, low-quality evidence is generally
available about home care and additional research would be
required [11].
Diabetic Foot care in home setting needs a multidisciplin-
ary approach provided by healthcare providers with home-
based abilities [13].In addition, there are some important chal-
lenges in this area such as lack of enough information about
the treatment costs and discriminatory terrif in Iran, and also
weakness in delivering home care service [14]. In Iran, we
face rising in the number of diabetic patients [15], so it is
important that more knowledge is gained about the effective-
ness and cost-effectiveness of different strategies such as
home care in patients with diabetes. Then we decided to con-
duct a clinical trial and cost evaluation, using dual-modality
measurements to compare the cost-effectiveness of care deliv-
ery at hospital vs. home in patients with DFU. We focused on
outcomes indicators in two groups of home and hospital care




We conducted a randomized controlled trial and an economic
evaluation study. The interventional study was in form of non-
equivalent and patients admitted in the hospital with diagnosis
of DFU were recruited in the trial. The participants were ran-
domly assigned into two groups considering the type of ser-
vices they were receiving whether home care or hospital care.
Inclusion criteria was a primary diagnosis of DFU (Wagner
stage 2, 3, 4 and Ankle Brachial Index (ABI) >0.5, patient’s
physician must agree with early discharge to home care ser-
vice (HCS), possibility to reside in Tehran city for patients in
home care group and exclusion criteria were unstable or non-
satisfied patients for transfer to the home care intervention.
The economic evaluation study was conducted to compare
the outcomes of diabetic foot treatment between the two mo-
dalities named hospital base and home care. This study was
implemented in a public teaching hospital affiliated to Tehran
University of medical sciences (from April 2016 to October
2017).
Sample size
Sample size was calculated according to 80% study power,
and also the probability of observation due to chance was 5%.
Finally, 120 patients were recruited using a systematic
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sampling technique (30 patients in home care services (HCS)
and 90 patients hospital-based care (HBC)).
Randomization and blinding
List of patients admitted with DFU in hospital were obtained
from bed manager’s daily, after examining the inclusion
criteria by one of the researchers (MA),who did not interface
in data gathering or intervention, the allocation was conducted
through the block randomization. In this regard, a numerical
list generated by excel software was used. Then, the partici-
pants were categorized into four blocks and then 1 and 3
patients randomly entered to HCS and HBC, respectively.
Participants were selected and evaluated by the same research-
er. Because of the nature of our intervention, we were unable
to mask patients but one of the research assistant who was
blinded after assignment to interventions was responsible for
the final evaluation of all participants based on the study mod-
el and outcomes assessment, too.
Health outcome measure
The outcomes included the rate of reduction in ulcer area, rate
of amputation, healed, death and infected ulcer, length of stay
and quality of life.
Intervention and data collection
An independent data collector team observed all admitted pa-
tients with DFU and collected patient’s information (including
age, sex, medical and clinical data and cost data). HBC re-
ceived conventional care while HCS receive the home care
treatment. After the patients were assigned into the modality
of treatment at home, a trained nurse, responsible for home
care, explained the purpose and procedure of the study to the
patient and his/her family. If patient agreed to continue treat-
ment at home, the home care provider team was introduced to
the patient and the hospital discharge process was arranged
accordingly. The patient was then discharged and received
HBHC for an average 3–4 weeks. However, this period ex-
tended for some patients based on physician’s clinical judg-
ment. Home care providers were active 24 h a day, 7 days a
week and were available to be contacted by patients when
need raised. In addition, patients were also able to contact a
senior hospital nurse, at every hour of the day. Also, patients
under the HBHC had full access to the hospital services led by
the senior HBHC nurse. The treatment of patients with diabet-
ic foot ulcer was performed according to the clinical guideline
approved by the Ministry of Health in Iran. The home visit
team consisted of a general practitioner (GP) and 3 nurses.
Average duration of each visit was 30–40 min. Following
the initial home visit, additional home visits were conducted
at least once a week. One ratter person was sent as an observer
to the patient’s home once a week to monitor the process of
home care services and to interview patients. In addition, fur-
ther information on study outcomes was obtained at the end of
intervention for the sake of study.
Statistical methods
The continuous variables were tested for normality situation,
and the Mann-Whitney U test was used for calculating the
average differences, the T student for continuous variables,
and the Chi square for categorical variables. In order to ex-
press the differences between the two groups in terms of
healing and amputation rates, a multivariate binary logistic
regression was performed at a significant level of %5- to con-
trol the effect of confounding variables such as age, duration
of disease, smoking, family history, location of ulcers, and
antibiotic use. All analyses were performed based on intention
to treat (ITT) analysis. A summary of the statistical findings of
the study population at the baseline (i.e., age, sex, duration and
type of diabetes, employment situation) are presented for con-
trol and intervention groups using descriptive tests (i.e., mean
and median).
Decision analysis model
Based on the gained clinical evidence in trial phase and com-
piled cost data, the decision tree model was designed for cost-
effectiveness analysis in which twomodalities named of HBS,
HCS. In this model, 30 patients were included in the HCS and
90 patients were enrolled in HBS. Our model consists of 5
states; healed, gangrened, amputation, infectious, and death
that was extracted from other studies and was approved by a
focus group discussion Therefore, in terms of reliability and
reliability, it is at the appropriate level. Meanwhile the men-
tioned stages considered based on patient situation after
6 months (See model in Fig. 1).
Model inputs
Cost data, quality-adjusted life year (QALY) and the possibil-
ity of 5 stages in each modalities. (See Fig. 1).
Effectiveness
Health outcome is specified in terms of QALY. It be consid-
ered as a measurement that combines the number of lived
years with the quality of those years. We obtained utility
scores using EQ-5D questionnaires administered via face-to-
face interviews in the base-time and by phone in follow-up
period at 6 months after discharge from home care and hospi-
tal care (±2 weeks). The missing data was specified in follow-
up period, then we imputed missing data by R software based
on Edwards’ study; we assumed the similarity in utility score
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across the two study groups in the base-time as well as using
the straight line transitions between baseline and follow up
[16, 17]. After that we multiplied the follow-up utility scores
data in the study period (6 months equivalent 0.5 year).
Meanwhile, any deaths were registered as zero in the utility
for the assessment period.
Resource use measurements
The resource use measurements included both direct (medical,
non-medical) and indirect costs. Cost of data was collected
from 120 included patients treated in hospital and home care
modalities retrospectively based on study group from social
perspective. Cost information was obtained from various
sources including hospital information system, accounting
unit, patients’ records, and through completing the question-
naire by asking the patient or his/her family. The resources
were categorized into medical cost including in-patient and
out-patient services (i.e., hospitalization cost, out-patient sur-
gery, physicians’ visits, nurses’ visits, physiotherapists’ and
occupational therapists’ visits, X-ray and lab examinations
and relevant pharmaceuticals for Diabetic patients) and non-
medical costs (e.g., travel expenses, accommodation) and in-
direct costs (loss of production).
Table 1 Demographic data of the subjects (N = 120)
HCS HBC
Item N % N %
sex (male) 22 73 58 64
age (Ave, SD) 61.7 (11.1) – 58.5 (10.9) –
Los (days, AVE) 20 – 19.9 –
Employment 10 34 23 25
type of diabetes 20 66 74 82
type 1 2 5 4 4
type 2 28 95 86 95
length of illness
5> 3 10 9 10
6–10 3 10 24 26
< 11 24 80 57 63
HCS, home care services; HBC, hospital-Based care





Type of wound (N, %) Ischemic 15 (15%) 5 (16%)
Nouroischemic 19 (19%) 10 (30%)
Nouropathy 59 (60%) 14 (46%)
Vein ulcer 5 (5%) 2 (6%)
Severity of ulcer (N, %) Wagner 2 46 (51%) 8 (26%)
Wagner 3 28 (31%) 19 (63%)
Wagner 4 16 (17%) 3 (1%)
Sepsis (N, %) Mild 19 3
Moderate 32 6
Sever 19 3
Initial wound size ulcer
Cm2 (N, %)
Total 3.46 (2.34) 3. 24 (1.89)
≤1 cm2 21 (23%) 5(16%)
1–5 cm2 50 (55%) 17 (56%)
>5 cm2 19 (21) 8(26)
*Significant
Fig. 1 Decision tree modeling for the cost- effectiveness of patient with DFU
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Aforementioned costs for each patient were calculated.
Afterwards the costs of patients according to the model clas-
sification were accumulated. To calculate the cost of each arm
of the decision tree model, the average cost per patient was
considered. In our model, costs were evaluated based on time
study for 6 months. Costs were calculated based on US dollar
(Cost is calculated on the basis of US dollars in 2017; each
dollar equivalent 42,000 Rail).
By comparing the costs and effectiveness of two modalities,
we calculated the incremental cost effectiveness (ICER), the
ratio of the ICER (R) was calculated from the below formula:
Where CC and UC are average costs and effectiveness in
the control group (HBC), CT, UT represents average cost and
effectiveness in the treatment group (HCS).This ratio projects
a point estimate of the average costs per QALY. Tree Age Pro
2009 software was used for data analysis.
Sensitivity analysis
Tornado diagrams are used for deterministic sensitivity
analysis to investigate the effects of utility and cost and
probability data and also to determine the effect of the
plausible changes of these parameters on the stability and
generalizability of our model.
The sensitivity analysis was performed for the parameters
with the greatest impact on the cost-effectiveness analysis. we
considered 20% changes in the parameters (utility and cost
and probability data) that was obtained from other studies
[18]. This study didn’t need time horizon for QALYand cost-
ing discounting.
Ethical consideration
The study protocol was approved by the Ethics Committee of
T e h r a n U n i v e r s i t y o f M e d i c a l S c i e n c e s
IR.TUMS.EMRI.REC.1395.0081 and was then registered at
the Iranian Center for Clinical Trials IRCT2017080935600N1.
Results
Patient characteristics
There was no significant difference between the HBC and HCS
groups in the demographic characteristics. These characteristics
of patients are shown in Table 1. The ages of two groups were
not significantly different (p = 0.36). The majority of subjects
were unemployed and above 50 years of age, and belonged to
middle socioeconomic level. Ninety percent of participants had
type 2 diabetes and suffered from DFU more than 5 years.
Diabetic foot ulcer
The most common type of ulcer was neuropathy in both groups
(Table 2). The wound were unilateral in 64% and bilateral in
5% of cases. Also, most of ulcers had moderate infection in
both groups. The Paired t-test showed that the size reduction
in HBC was significant (P value = 0.003) in comparison with
HCS. 38% of patients experienced complete healing after
4 weeks. 28% of patients did not show wound healing in
3 weeks (Wagner’s incremental changes, infections, gangrene,
and amputation). The ratio of the healed patients in the inter-
vention group was significantly higher than the controls, and
none of the patients underwent amputation in HCS group, 17%
of controls underwent amputation. Death was reported in 17%
of patients within 6 months after discharge (Table 3).
Economic evaluation
Table 4 shows the costs of two care modalities separately. The
average cost for the HCS and HBC were 1545 $ and 3891.4 $
(including medical, nonmedical and indirect costs), respec-
tively. To calculate the cost of each arm of the decision tree








reduction in ulcer area (mm2)
(mean, SD)
(−65.05,361.5) (−256. 445.2) <0.001
Rate of healed N (%) 28 (31%) 20 (66%) 0.01
Rate of amputation N (%) 16 (17%) 0 (0) 0.01
Rate of Death by 6 months N
(%)
15 (16%) 6 (20%) 0.6
Rate of Unhealed N (%) 30 (33%) 4 (13%) 0.03
Length of stay (days) Mean
(SD)
20.3 (14.5) 21 (1.01) 0.7
Table 4 Cost-data (costs in US dollars)
Control group Intervention group





Total Medical cost 3001 1119.73
non-medical costs 413.4 264.2
indirect costs 525.9 336.5
Total cost 3940.3 1720.4
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model, the cost per patients in each arm accumulated, after
that averaged and included in study model.
Total effectiveness in the HCS group were more than HBC
group but this differences were not significant based on the
results of the statistical tests (p > 0.4).At baseline, the utility
weight was 0.72 and 0.69 for HBC and HCS groups, respec-
tively. After 6 mounts follow-up period, the HCS (0.63) and
HBC (0.58) had a decrease in the utility both of the groups.
QALY in the HCS and HBC groups were 0.31 and 0.29,
respectively (Mean diff −0.03, 95% CI -0.12 to 0.05).
Analysis of the cost and effectiveness data resulted in the
decision tree for two groups (HCS and HBC) showed that
cost-effectiveness (C/E) ratio was 1545 USD per QALY for
home care strategy and 3891 dollars per QALY for hospital
care strategy. Then, the superior arm for care of patients with
diabetic foot ulcer is home care intervention because these
patients gain more QALY with fewer costs. Figure 2 shows
the cost-effectiveness analysis in which the home care inter-
vention is located at the dominated region (Tables 5 and
6).Tornado diagram shown in Fig. 3 demonstrates that the
parameters had the greatest impact on ICER. But according
to the results of the One-way sensitivity analysis, the result of
HBC was not sensitive to changes in these variables.
Discussion
Based on the results of economic evaluation, HCS in patients
with DFU is more cost effective than HBC. The actual cost
saving was estimated based on costs per patient.
The results of a study by Haggerty,similar to the present
study, reported a reduction in the use of hospital resources and
health care costs following home care [19]. Some studies also
found a decrease in the use of hospital resources during home
care services [20]. The reduction in patient costs in the
Cumming study also points out that this cost reduction has
been linked to the reduction in occupancy rates for hospital
beds [21], Therefore, home care for some disease groups
seems to be cost-effective due their probable application to
use hospital resources for other patients. But HCS requires a
hardware and soft infrastructure that includes prediction
equipment for patients who can’t afford buying or rent equip-
ment (oxygen and suction, etc.), as well as the need for pro-
tocols for diseases that indicate the transition to home care.
The study of Oldridgeet al examined the costs and quality
of life of patients with acute heart failure during the 8-week in
2 groups who received home care and hospital care.
Following the treatment, they reported that ICER and QALY
Fig. 2 Cost-effectiveness ratios
on the cost- effectiveness plane
Table 5 The incremental cost-
effectiveness ratio (costs in US
dollars)
Intervention Effectiveness Incremental effectiveness Cost Incremental cost ICER
Home care 0.31 – 1545 – –
Hospital care 0.29 0.02 3891 −2346 −117,300
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were $ 480 and $ 0.052 and ICERwas $ 9200 per QALY [22].
The finding of the so called study is similar to the results of
this study.
To the best of our knowledge, the study did not address the
cost effectiveness of treating diabetic foot ulcers at home and
in the hospital. Therefore, there was hardly any clinical and
costly evidence to compare treatment in this disease.
Limited studies were conducted on the safety of home-
based treatment that has adequate strength and the assessment
of the risks of adverse events. Because some studies
pinpointed that limiting the spread of this type of treatment
is limited by the inability to carry out some homeopathic treat-
ments at home. Therefore, there is a significant gap in the
published studies on the safety of home care as well as some
disease groups such as diabetic foot ulcers.
Cost analysis in HCS isn’t under the coverage of health in-
surance system as well as different cost-accounting studies still
require trial studies with acceptable sample sizes. The type of
treatment at home and the difference between home care and the
hospital are affected by actual and not necessarily patient billing.
And the difference between studies comes from whether only
direct costs or indirect costs are taken into account. Stevens’
study reported no efficiently, in discussing financial aspects,
spending does not arise from the perspective of the community,
so their interpretation should be cautious [23].
Limitation
Despite the long duration of the study, the number of patients
receiving HCS was less than HBC because the majority of
patients did not have possibility of residency in Tehran city
as a one of the inclusion criteria and consequently, they didn’t
enter into the study.
Fig. 3 Tornado diagram for
sensitivity analysis
Table 6 Cost and effectiveness comparison based on the model
State Control group Intervention group
Ave cost ($) QALY Ave cost ($) QALY
Infected 3404.59 0.28 1903.71 0.30
Gangrene 1691.04 0.28 – –
Amputation 7377.31 0.29 – –
Healed 2508.85 0.28 1628.34 0.28
Death 4473.45 0 1105.62 0
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Conclusion
The results of this study showed that HCS delivery for patients
with DFU is more cost effectiveness than hospital care.
Considering that home care services in Iran doesn’t have pos-
sibility to be provided for all patients admitted to the hospital
and isn’t covered by the health insurance, the implementation
of home care services may be challenging. Therefore, it is
suggested that healthcare policy makers should determine
the tariff for health care services for disease groups according
to the ABC approach and different tariff’s should be applied to
home care based on severity, type of disease, and equipment in
patients.
Acknowledgments The authors announce so gratefully acknowledge the
substantial contribution of all scientific and executive personnel of EMRI
and Dr.Shariati Hospital. Also we would like to thank from Dr. Kamran
Shayanfard form University of Luxembourg for his help and guidance in
statistics parts.
Authors’ contributions ZN: Designing the methodology, reviewing of
the literatures, and writing the original article.
MA, MM: Performed randomization and supervision on HBS provid-
er performance
ZN, ZG: Cleaning and analyzing data (data imputed and economic
evaluation)
MJ: Doing requirement research at hospital
MS, MA: Editing the article
All authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest The authors declare that there is no conflict of inter-
est regarding the publication of this article.
Ethics issues The study protocol was approved by the Ethics Committee
o f T e h r a n U n i v e r s i t y o f M e d i c a l S c i e n c e s
IR.TUMS.EMRI.REC.1395.0081 and was then registered at the Iranian
Center for Clinical Trials IRCT2017080935600N1.
References
1. Gomes B, Calanzani N, Curiale V, McCrone P, Higginson IJ, Brito
Md: Effectiveness and cost-effectiveness of home palliative care
services for adults with advanced illness and their caregivers. Sao
Paulo Medical Journal 2016, 134(1):93–94.
2. Wu SC, Armstrong DG. Clinical outcome of diabetic foot ulcers
treated with negative pressure wound therapy and the transition
from acute care to home care. Int Wound J. 2008;5:10–6.
3. Hall V, Thomsen RW, Henriksen O, Lohse N. Diabetes in Sub
Saharan Africa 1999–2011: epidemiology and public health impli-
cations. A systematic review. BMC Public Health. 2011;11(1):564.
4. Unit EI. The quality of death: ranking end-of-life care across the
world. London: The Economist; 2010.
5. Hatmi Z, Tahvildari S, Motlag AG, Kashani AS. Prevalence of
coronary artery disease risk factors in Iran: a population based sur-
vey. BMC Cardiovasc Disord. 2007;7(1):32.
6. Ward D, Drahota A, Gal D, Severs M, Dean TP: Care home versus
hospital and own home environments for rehabilitation of older
people. The Cochrane Library 2008.
7. Armstrong DG, Lavery LA. Diabetic foot ulcers: prevention, diag-
nosis and classification. Am Fam Physician. 1998;57(6):1325–32
1337-1328.
8. Caplan GA, Sulaiman NS, Mangin DA, Aimonino Ricauda N,
Wilson AD, Barclay L. A meta-analysis of “hospital in the home”.
Med J Aust. 2012;197(9):512–9.
9. Joret MO, Dean A, Cao C, Stewart J, Bhamidipaty V. The financial
burden of surgical and endovascular treatment of diabetic foot
wounds. J Vasc Surg. 2016;64(3):648–55.
10. Cavanagh P, Attinger C, Abbas Z, Bal A, Rojas N, Xu ZR. Cost of
treating diabetic foot ulcers in five different countries. Diabetes
Metab Res Rev. 2012;28:107–11.
11. Bryant-Lukosius D, Carter N, Reid K, Donald F, Martin-Misener R,
Kilpatrick K, et al. The clinical effectiveness and cost-effectiveness
of clinical nurse specialist-led hospital to home transitional care: a
systematic review. J Eval Clin Pract. 2015;21(5):763–81.
12. Templeton S, Wong C, Rando T, Adamson P, Lynn P. Microbial
contamination of open-but-unused portions of wound dressings
stored in home settings. Int Wound J. 2018;15(1):106–13.
13. Meah YS, Gliatto PM, Ko FC, Skovran D: Wound care in home-
based settings. In: Geriatric Home-Based Medical Care. edn.:
Springer; 2016: 195–236.
14. Nikbakht-Nasrabadi A, Shabany-Hamedan M. Providing
healthcare services at home-a necessity in Iran: a narrative review
article. Iran J Public Health. 2016;45(7):867.
15. Rashedi V, Asadi-Lari M, Delbari A, Fadayevatan R, Borhaninejad
V, Foroughan M. Prevalence of diabetes type 2 in older adults:
findings from a large population-based survey in Tehran, Iran (ur-
ban HEART-2). Diabetes & Metabolic Syndrome: Clinical
Research & Reviews. 2017;11:S347–50.
16. Edwards R, Hounsome B, Russell D, Russell I, Williams N, Linck
P: QALY calculation alongside randomised controlled trials: from
the torch to the traffic light. In: 1st Franco-BritishMeeting in Health
Economics CES/HESG, Paris: 2004; 2004.
17. Vickers AJ, Altman DG. Analysing controlled trials with baseline
and follow up measurements. Bmj. 2001;323(7321):1123–4.
18. Sari AA, Ravaghi H, Mobinizadeh M, Sarvari S. The cost-utility
analysis of PET-scan in diagnosis and treatment of non-small cell
lung carcinoma in Iran. Iran J Radiol. 2013;10(2):61.
19. Haggerty MC, Stockdale-Woolley R, Nair S. Respi-care: an inno-
vative home care program for the patient with chronic obstructive
pulmonary disease. Chest. 1991;100(3):607–12.
20. Clini E, Vitacca M, Foglio K, Simoni P, Ambrosino N. Long-term
home care programmes may reduce hospital admissions in COPD
with chronic hypercapnia. Eur Respir J. 1996;9(8):1605–10.
21. Cummings JE, Hughes D, Manheim LM. Hospital-based home
care. Arch Intern Med. 1990;150:1274–80.
22. Oldridge N, Furlong W, Feeny D, Torrance G, Guyatt G, Crowe J,
et al. Economic evaluation of cardiac rehabilitation soon after acute
myocardial infarction. Am J Cardiol. 1993;72(2):154–61.
23. Stevens B, Croxford R, McKeever P, Yamada J, Booth M, Daub S,
et al. Hospital and home chemotherapy for children with leukemia:
a randomized cross-over study. Pediatr Blood Cancer. 2006;47(3):
285–92.
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
J Diabetes Metab Disord
